#1) 150 milligram per cubic metre, bid #1) Oral use																		CI	OI	MS	FO	R	M	
1. REACTION INFORMATION 1. NOTICE! INFORMATION 2. DATE OF BETT! 2. AGE 5. SEX 3. WEIGHT 4. REACTION-ONSET 2. DATE OF BETT! 2. AGE 5. SEX 3. WEIGHT 4. REACTION-ONSET 2. DATE OF BETT! 2. AGE 5. SEX 3. WEIGHT 4. REACTION-ONSET 2. DATE OF BETT! 2. AGE 5. SEX 3. WEIGHT 4. REACTION-ONSET 2. DATE OF BETT! 2. AGE 5. SEX 3. WEIGHT 4. REACTION-ONSET 2. DATE OF BETT! 2. AGE 5. SEX 3. WEIGHT 4. REACTION-ONSET 2. DATE OF BETT! 2. AGE 5. SEX 3. WEIGHT 4. REACTION-ONSET 2. DATE OF BETT! 2. AGE 2. AGE 3. SEX 3. WEIGHT 4. REACTION-ONSET 4. AGE 4																								
S. DALLY CONTROL Security S	SUSPECT AD	VERSE F	REAC	OIT	I REP	ORT																	┨	
S. DALLY CONTROL Security S											1	П	\top	Т	Τ	Т		Т	Т	Т	\top	Т	\dashv	
S. PARTINE NOTATES INCLUDIENCE 1972 More 1972																								
PRIVACY EL SALVADOR Day PRIVACY Part Privacy Part Privacy					I. RE	EACTI	ION	INFO	RMATIO	N														
PRIVACY PRIVACY PRIVACY OIR Feffrale kg NOV 2024 NOV 2024 NOV 2024 NOV 2024 NOV 2024 NOV 2025 N	(first, last)					_	AGE	3. SEX		-	_					8-12	CH AF	HECK	(AI)PF	LL RIAT	E TO	0		
In Suspect drugs Industry I	PRIVACY EL SA	ALVADOR					nk	(!								
Event Verbatini (PREFERRED TERM) (Related symptoms if any separated by commiss) Product Serious Usted Causality Company Causality Causa				data)																				
ANALY CONTINUED TO PRIVATE Separated by commass) Floration Separated by commass) Floration Separated by Causality		, ,								Dor	orto					Ш	PRO	DLONG	GED	INPAT	IENT			
II. SUSPECT DRUG(S) (include genetic name) III. SUSPECT DRUG(S) INFORMATION III. SUSPECT DRUG(S) ADMINISTRATION III. SUSPECT DRUG(S) ADMINISTRATION III. SUSPECT DRUG(S) ADMINISTRATION III. SUSPECT DRUG(S) INFORMATION III. SUSPECT DRUG(S) ADMINISTRATION III. SUSPECT DRUG(S) INFORMATION III. SUSPECT DRUG(S) ADMINISTRATION III. SUSPECT DRUG(S) ADMINISTRATION III. SUSPECT DRUG(S) III. SUSPECT DRUG(S) INFORMATION III. SUSPECT DRUG(S) III. SU	symptoms if any separated by	commas)	a				_			Cai	Causality Causality						OR	SIGNIF	FICA	NT	ENT			
(Continued on Additional Information Page) II. SUSPECT DRUG(S) INFORMATION III. DRUTP(S) OF ADMINISTRATION III. DRUTP(S) AND DRUTP(S) AND DRUTP(S) AND DRUTP(S) AND HISTORY III. CONCOMITANT DRUG(S) III. CONCOMITANT DRUG(S) III. CONCOMITANT D	INAUSEA			OLAI	AIND		'	163	res Related Related					cu		_	INC	APACI						
II. SUSPECT DRUG(S) (include generic name) III. SUSPECT DRUG(S) INFORMATION																Ш	THE	REATE		3				
II. SUSPECT DRUG(S) (include genetic name) III. SUSPECT DRUG(S) INFORMATION 20 ID REACTION 20 ID REA																								
14. SUBPECT DRUG(S) (include generic name) 20. DIR REALTION AND LATER TERR STOPPING MILE THE RESTOPPING MILE MIL								(Cont	inued on Ad	dition	al In	format	tion	Pag	e)	\boxtimes	ОТН	HER						
## 10 OLAPARIB (OLAPARIB) Tablet ## 1 OLAPARIB (OLAPARIB) Tablet ## 1 Oral use				11 .5	SUSPE	ЕСТ Г)RI	IG(S) II	VEORM	ΔΤΙζ	NC								_				_	
15. DAILY DOSE(S) 15. DAILY DOSE(S) 15. ROUTE(S) OF ADMINISTRATION 15. ROUTE(S) OF ADMINISTRATION 17. INDICATIONS 17. INDICATI				11. C	, , , , , , , , , , , , , , , , , , ,	_01 _	7110) (O) II	VI OTAIVI	TITC	<i>)</i> 1]					ODDIA	10			
#1) 150 milligram per cubic metre, bid #1) Oral use	#1) OLAPARIB (OLAPARI	IB) Tablet																	. 510	OPPIN	IG			
17. INDICATION(S) FOR USE 19. THERAPY DURATION 19. THERAPY DUR	15. DAILY DOSE(S)	i bid																Tyes I NO MAA						
#1) Breast cancer (Breast cancer) REAPPEAR AFTER REINTRODUCTION? 19. THERAPY DURATION	#1) 150 milligram per cubi	ic metre, bla					f-	41) Oran t	ise								_	[,] Ц						
III. CONCOMITANT DRUG(S) AND HISTORY 22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) 19. THERAPY DURATION	17. INDICATION(S) FOR USE #1) Breast cancer (Breast	cancer)															REAPPEAR AFTER							
#1) NOV-2024 / Unknown #1) Unknown #1) Unknown	, ,	,					T ₁	10 THERAD	/ DURATION						4	IXL		ЮВОО	1101	IN:				
22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) 23. OTHER RELEVANT HISTORY, (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates Type of History / Notes Description Unknown to Ongoing Indication Breast cancer (Breast cancer) IV. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER AstraZeneca Serban Ghiorghiu 1 Medimmune Way 2 Mord Wiley #: SV-ASTRAZENECA-202505CAM012277SV Study ID: PSP-23269 Case References: SV-AstraZeneca-CH-00871003A 24b. MFR CONTROL NO. 202505CAM012277SV 25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.	#1) NOV-2024 / Unknown																YES NO NA							
22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) 23. OTHER RELEVANT HISTORY, (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates Type of History / Notes Description Unknown to Ongoing Indication Breast cancer (Breast cancer) IV. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER AstraZeneca Serban Ghiorghiu 1 Medimmune Way 2 Mord Wiley #: SV-ASTRAZENECA-202505CAM012277SV Study ID: PSP-23269 Case References: SV-AstraZeneca-CH-00871003A 24b. MFR CONTROL NO. 202505CAM012277SV 25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.																							J	
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates Unknown to Ongoing Indication IV. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER AstraZeneca Serban Ghiorghiu 1 Medimmune Way Gaithersburg, Maryland 20878 Phone: +1 301-398-0000 24b. MFR CONTROL NO. 202505CAM012277SV NAME AND ADDRESS OF REPORTER 25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.	22 CONCOMITANT DRUG(S) AND	DATES OF ADM							S) AND I	HIS ⁻	ГОБ	RY											_	
IV. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER AstraZeneca Serban Ghiorghiu 1 Medimmune Way Gaithersburg, Maryland 20878 UNITED STATES Phone: +1 301-398-0000 24b. MFR CONTROL NO. 202505CAM012277SV Description Breast cancer (Breast cancer) Description Breast cancer Breast cancer 26. REMARKS World Wide #: SV-ASTRAZENECA-202505CAM012277SV Study ID: PSP-23269 Case References: SV-AstraZeneca-CH-00871003A 25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.	22. CONCOMITANT DRUG(S) AND	DATES OF ADIV	IIIVIOTINA	iion (ex	cidde tilose	e useu to ti	ieal ie	saction)																
IV. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER AstraZeneca Serban Ghiorghiu 1 Medimmune Way Gaithersburg, Maryland 20878 UNITED STATES Phone: +1 301-398-0000 24b. MFR CONTROL NO. 202505CAM012277SV Description Breast cancer (Breast cancer) Description Breast cancer Breast cancer 26. REMARKS World Wide #: SV-ASTRAZENECA-202505CAM012277SV Study ID: PSP-23269 Case References: SV-AstraZeneca-CH-00871003A 25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.																								
IV. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER AstraZeneca Serban Ghiorghiu 1 Medimmune Way Gaithersburg, Maryland 20878 UNITED STATES Phone: +1 301-398-0000 24b. MFR CONTROL NO. 202505CAM012277SV Description Breast cancer (Breast cancer) Description Breast cancer Breast cancer 26. REMARKS World Wide #: SV-ASTRAZENECA-202505CAM012277SV Study ID: PSP-23269 Case References: SV-AstraZeneca-CH-00871003A 25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.																								
IV. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER AstraZeneca Serban Ghiorghiu 1 Medimmune Way Gaithersburg, Maryland 20878 UNITED STATES Phone: +1 301-398-0000 24b. MFR CONTROL NO. 202505CAM012277SV Description Breast cancer (Breast cancer) 26. REMARKS World Wide #: SV-ASTRAZENECA-202505CAM012277SV Study ID: PSP-23269 Case References: SV-AstraZeneca-CH-00871003A																								
IV. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER AstraZeneca Serban Ghiorghiu 1 Medimmune Way Gaithersburg, Maryland 20878 UNITED STATES Phone: +1 301-398-0000 24b. MFR CONTROL NO. 202505CAM012277SV 25b. NAME AND ADDRESS WITHHELD.	From/To Dates	(e.g. diagnostics,	Ty	pe of His	tory / Notes		period	Description	-															
24a. NAME AND ADDRESS OF MANUFACTURER AstraZeneca Serban Ghiorghiu 1 Medimmune Way Gaithersburg, Maryland 20878 UNITED STATES Phone: +1 301-398-0000 24b. MFR CONTROL NO. 202505CAM012277SV 26. REMARKS World Wide #: SV-ASTRAZENECA-202505CAM012277SV Study ID: PSP-23269 Case References: SV-AstraZeneca-CH-00871003A 25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.	Unknown to Ongoing		Ir	ndicatio	on			Breast o	ancer (Bre	east o	canc	er)												
24a. NAME AND ADDRESS OF MANUFACTURER AstraZeneca Serban Ghiorghiu 1 Medimmune Way Gaithersburg, Maryland 20878 UNITED STATES Phone: +1 301-398-0000 24b. MFR CONTROL NO. 202505CAM012277SV 26. REMARKS World Wide #: SV-ASTRAZENECA-202505CAM012277SV Study ID: PSP-23269 Case References: SV-AstraZeneca-CH-00871003A 25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.																								
24a. NAME AND ADDRESS OF MANUFACTURER AstraZeneca Serban Ghiorghiu 1 Medimmune Way Gaithersburg, Maryland 20878 UNITED STATES Phone: +1 301-398-0000 24b. MFR CONTROL NO. 202505CAM012277SV 26. REMARKS World Wide #: SV-ASTRAZENECA-202505CAM012277SV Study ID: PSP-23269 Case References: SV-AstraZeneca-CH-00871003A 25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.																								
24a. NAME AND ADDRESS OF MANUFACTURER AstraZeneca Serban Ghiorghiu 1 Medimmune Way Gaithersburg, Maryland 20878 UNITED STATES Phone: +1 301-398-0000 24b. MFR CONTROL NO. 202505CAM012277SV 26. REMARKS World Wide #: SV-ASTRAZENECA-202505CAM012277SV Study ID: PSP-23269 Case References: SV-AstraZeneca-CH-00871003A 25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.				N /				DED 14											_					
Serban Ghiorghiu 1 Medimmune Way Gaithersburg, Maryland 20878 UNITED STATES Phone: +1 301-398-0000 24b. MFR CONTROL NO. 202505CAM012277SV Study ID: PSP-23269 Case References: SV-AstraZeneca-CH-00871003A 25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.	24a. NAME AND ADDRESS OF MA	NUFACTURER		IV.	MANU	UFAC	10			<u> </u>	N												\neg	
1 Medimmune Way Gaithersburg, Maryland 20878 UNITED STATES Phone: +1 301-398-0000 24b. MFR CONTROL NO. 202505CAM012277SV Case References: SV-AstraZeneca-CH-00871003A 25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.	AstraZeneca Serban Ghiorghiu											ZENE	ECA	-20	2505	CAN	/1012	22775	SV					
24b. MFR CONTROL NO. 202505CAM012277SV 25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.	1 Medimmune Way Gaithersburg, Maryland 20878 UNITED STATES											raZen	eca	-CH	300-l	3710	03A							
202505CAM012277SV NAME AND ADDRESS WITHHELD.	Phone: +1 301-398-0000																							
202505CAM0122775V		24b. MFR CO	NTROL N	NO.															_				ᅥ	
		202505CAM012277SV							E AND ADI	DRES	S W	/ITHH	ELD).										
24c. DATE RECEIVED BY MANUFACTURER 24d. REPORT SOURCE STUDY LITERATURE	24c. DATE RECEIVED BY MANUFACTURER	24d. REPORT	r sourc		TERATURI	E																		
40 MAN/ 000F	19-MAY-2025	NOT																						
DATE OF THIS REPORT 25a. REPORT TYPE	DATE OF THIS REPORT 20-MAY-2025	25a. REPORT						\exists																

X INITIAL

FOLLOWUP:

Mfr. Control Number: 202505CAM012277SV

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

Case Description: A solicited report has been received from a other health professional in Patient Support Program. The report concerns a female patient (age not provided) of Unknown ethnic origin (height 165 cm, weight 200 kg).

No medical history was reported.

No concomitant products were reported.

The patient started treatment with Olaparib (olaparib) 150 milligram per cubic metre bid, Oral use, on an unknown date for breast cancer.

On an unknown date, the patient experienced nausea (preferred term: Nausea).

It is unknown if any action was taken with Olaparib (olaparib).

The patient recovered from the event(s) nausea on an unspecified date.

The event was considered serious (Medically Significant).

The reporter considered that there was a reasonable possibility of a causal relationship between Olaparib and the following event(s): nausea.

The company physician considered that there was a reasonable possibility of a causal relationship between Olaparib and the following event(s): nausea.